MOTS-c is a peptide: a short chain of amino acids, the building blocks of proteins. It isn’t gene therapy, a treatment that supplies or changes genetic instructions. The peptide itself isn’t a living cell or a whole cell part.
Many MOTS-c myths start with its name. Mitochondria are the parts of cells that help turn food into usable energy. They contain some DNA, the instructions cells use to make molecules. MOTS-c's instructions sit there. The finished peptide is a different thing from those instructions.
Here are ten claims, graded against the studies behind them.
MOTS-c myths: is MOTS-c gene therapy?
1. “The human body already makes MOTS-c.”
Supported. The 2015 discovery paper in Cell Metabolism identified a peptide made of 16 amino acids and detected it in human blood. Its instructions are in mitochondrial DNA, but the paper places peptide production in the cytoplasm, the fluid surrounding a cell's internal parts. “Mitochondrial” names the origin of its instructions; it does not mean mitochondria manufacture the finished peptide inside themselves. Our MOTS-c and exercise guide covers a separate question: what happens with physical activity.
2. “MOTS-c is a piece of mitochondrial DNA.”
Not supported. A peptide is a chain of amino acids; DNA is made from different building blocks. The discovery paper describes DNA that encodes MOTS-c, meaning it carries instructions for making that peptide. It does not describe the finished peptide as DNA. A molecule's recipe and the molecule made from it are not interchangeable.
3. “Taking MOTS-c is gene therapy.”
Not supported. Receiving a peptide is different from receiving genetic instructions or a tool that changes DNA. FDA's gene-therapy guidance describes products that work through transferred genetic material or specifically alter human gene sequences. Giving MOTS-c as a peptide does not, by itself, meet that description. Effects on a cell's signals do not turn every medicine into gene therapy.
Does MOTS-c change DNA or gene activity?
4. “MOTS-c edits your DNA.”
Not supported. A 2018 Cell Metabolism study found MOTS-c entering the nucleus, the cell compartment holding most of its DNA. In laboratory experiments, it also bound to parts of DNA involved in controlling gene activity. Binding near a gene is different from editing its sequence, meaning changing the letters of its instructions. That paper did not demonstrate DNA editing.
5. “MOTS-c can change which genes a cell uses.”
Partly. The same study found changes in gene expression, meaning how actively cells use particular instructions, under stressful conditions such as low fuel. Some cells were engineered to make marked MOTS-c for tracking; others received peptide from outside the cell. Those are laboratory methods, not evidence that a person receiving the peptide receives altered genes. They also do not establish the outcomes discussed in our MOTS-c and aging guide.
Is MOTS-c stem cell therapy or a transplant?
6. “MOTS-c is mitochondrial transplantation.”
Not supported. Mitochondrial transplantation moves whole mitochondria into other cells, rather than giving a peptide. As of November 12, 2026, the day this article was written, a study published online August 14, 2026 used a modified MOTS-c gel to carry separately isolated mitochondria in rats. The peptide helped form a carrier; whole mitochondria were separate cargo. MOTS-c alone was not the transplant.
7. “MOTS-c is stem cell therapy.”
Not supported. Stem cells are living cells that can renew themselves and develop into other cell types. The discovery paper identified MOTS-c as a peptide, not a living cell. A study can test a peptide on cells without making the peptide a cell treatment. The name of the cells in an experiment does not tell you what is inside a prescribed preparation.
Is MOTS-c made from human tissue?
8. “MOTS-c has to be harvested from a person's tissue.”
Not supported. Its amino acid chain can be built chemically; extraction from donated tissue is not required. As of November 12, 2026, the day this article was written, a paper published in eLife on August 18, 2026 describes chemically synthesized MOTS-c. That establishes how the study's peptide was made. It does not establish the source of every preparation carrying the name.
9. “Synthetic MOTS-c means a genetically engineered version.”
Not supported. “Synthetic” means made, and chemical synthesis joins amino acids into a chain. It does not, by itself, mean the amino acid sequence was changed or that genetic material was added. A changed sequence is a separate question, covered in our MOTS-c versus CB4211 comparison. For a particular preparation, ingredient and manufacturing records matter more than the word “human” or “synthetic” on its own.
Does natural origin establish safety?
10. “The body makes it, so extra MOTS-c is safe.”
Unknown. Natural production does not establish the safety of a prescribed amount, a particular preparation or long-term exposure. As of November 12, 2026, the day this article was written, the MOTS-MET human trial record has no posted results. A registered trial is a plan to collect evidence, not a reassuring result. Our MOTS-c side-effects guide separates reported findings from the remaining safety questions.
What a prescription does establish
MOTS-c prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As of November 12, 2026, the day this article was written, FDA explains that it does not review compounded medications for safety, effectiveness and quality before they are marketed.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. That review is a place to discuss the intended goal, health history and remaining uncertainties. Questions about a preparation's ingredients belong with the dispensing pharmacy; questions about its fit for you belong with the prescriber.





